PreveCeutical Announces Change of Auditors
PreveCeutical Announces Change of Auditors
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that the Company has changed its auditor from Smythe LLP, Certified Public Accountants ("Former Auditor") to Davidson & Company LLP, Certified Professional Accounts ("Successor Auditor") effective December 18, 2024.
不列颠哥伦比亚省温哥华--(资讯 CORP - 2024年12月18日) - PreveCeutical 医疗公司 (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("公司"或"PreveCeutical"), 宣布公司已将审计师由 Smythe LLP 注册会计师 ("前审计师") 更换为 Davidson & Company LLP 注册专业会计师 ("继任审计师"), 自2024年12月18日起生效。
PreveCeutical's board of directors accepted the resignation of the Former Auditor and appointed the Successor Auditor as the new auditor of the Company effective December 18, 2024, and to hold office until the close of the Company's next annual general meeting of shareholders.
PreveCeutical 的董事会接受了前审计师的辞职,并于2024年12月18日起聘请继任审计师为公司的新审计师,并在公司下一次股东年度大会结束之前担任职务。
There were no reservations in the Former Auditor's audit reports for any financial period during which the Former Auditor was the Company's auditor. There are no "reportable events" (as the term is defined in National Instrument 51-102 - Continuous Disclosure Obligations) between the Company and the Former Auditor.
在前审计师担任公司审计师期间,没有任何财务期间的审计报告存在保留意见。公司与前审计师之间没有 "报告事项" (此术语在国家工具51-102 - 持续披露义务中定义)。
In accordance with National Instrument 51-102, the Notice of Change of Auditor, together with the required letters from the Former Auditor and the Successor Auditor, have been reviewed by the Company's audit committee and board of directors and will be filed on SEDAR accordingly.
根据国家工具51-102,审计师更换通知以及前审计师和继任审计师的相关信件已由公司的审计委员会和董事会审查,并将相应提交至 SEDAR。
About PreveCeutical
关于PreveCeutical
PreveCeutical is a health sciences company focused on developing innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.
PreveCeutical 是一家医学科学公司,专注于开发使用有机和自然相同产品的创新预防和治愈疗法。公司旨在成为预防医学科学板块的领导者。
With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.
在完成三项研究项目后,公司的产品开发、临床试验和商业化工作正在积极进行,并已提交多项临时专利申请以保护其研究项目的知识产权。
For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook.
欲了解更多关于 PreveCeutical 的信息,请访问我们的官方网站或在 Twitter 和 Facebook 上关注我们。
On behalf of the Board of Directors of PreveCeutical
代表PreveCeutical的董事会
Stephen Van Deventer, Chairman, Chief Executive Officer and interim Chief Financial Officer
Stephen Van Deventer,董事长,首席执行官及临时首席财务官
For further information, please contact:
如需更多信息,请联系:
Stephen Van Deventer: +1 604 306 9669
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.com
或投资者关系 ir@preveceutical.com
Forward-Looking Statements
前瞻性声明
Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the Company's plans relating to the development, clinical trials and commercialization of its products; and management expectations that it will miss the filing deadline for the Annual Filings and the Company's ability to file the Annual Filings within the time period described herein.
关于前瞻性陈述的注意事项:本发布包含某些可能构成依据适用的加拿大证券法的前瞻性信息的陈述和信息。前瞻性陈述涉及未来事件或未来表现,反映了公司管理层对未来事件的预期或信念。通常,前瞻性陈述和信息可通过使用前瞻性术语如“打算”或“预期”,或这些词和短语的变体,或某些行为、事件或结果“可能”、“可以”、“应该”、“将”或“发生”等陈述来识别。此信息和这些陈述在此称为“前瞻性陈述”,并非历史事实,基于本新闻发布之日期作出,包括但不限于,关于未来计划、估计和预测的讨论声明,以及管理层对其预期和意图的声明,涉及公司与其产品的开发、临床试验及商业化相关的计划;以及管理层预期未能在上述时间范围内提交年度资料的能力。
These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the Company being unable to execute its business plans as intended; the Company being unable to file the Annual Filings in the proposed timeframe; recent market volatility; and the state of the financial markets for the Company's securities.
这些前瞻性陈述涉及众多风险和不确定性,实际结果可能与任何前瞻性陈述所暗示的结果有重大差异。这些风险和不确定性包括但不限于:公司无法如预期执行其业务计划;公司无法在提议的时间框架内提交年度资料;近期市场波动;以及公司证券的金融市场状况。
In making the forward-looking statements in this news release, the Company has applied certain material assumptions, including without limitation, that: the Company will be able to execute its business plans as intended; the Company will be able to file the Annual Filings in the proposed time frame.
在本新闻稿中做出的前瞻性声明中, 公司已应用某些重要假设,包括但不限于: 公司将能够按照预期执行其业务计划; 公司将能够在提议的时间框架内提交年度备案。
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
尽管公司管理层已试图识别可能导致实际结果与前瞻性声明或前瞻性信息中所含结果有重要差异的重要因素,但可能还有其他因素导致结果未能如预期、估算或意图那样。无法保证这些声明将被证明是准确的,实际结果和未来事件可能与此类声明中所预期的有重要差异。因此,读者不应对前瞻性声明和前瞻性信息置于过度信任。读者需谨慎,信赖此类信息可能不适合其他目的。公司不承担更新在此引用的任何前瞻性声明、前瞻性信息或财务展望的义务,除非根据适用的证券法规定。我们寻求安全港。